Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results

BEACON-IPF pivotal, adaptive Phase 2b/3 trial design implementation significantly accelerates bexotegrast development in IPF Data from completed 12 week Phase 2a imaging trial measuring...

Related Keywords

Australia ,Massachusetts ,United States ,Christopher Keenan ,Bernard Coulie ,European Union ,Oxford Finance ,Corporate Communications ,Youtube ,Drug Administration ,Linkedin ,Pliant Therapeutics Inc ,Novartis ,Australia Research Ethics Committee ,Nasdaq ,Facebook ,European Medicines Agency ,Chief Executive Officer ,Massachusetts General ,Enhanced Liver Fibrosis ,Research Ethics Committee ,Pliant Therapeutics ,Fast Track Designation ,Orphan Drug Designation ,Private Securities Litigation Reform Act ,Financial Condition ,Quarterly Report ,Media Contact ,Investor Relations ,Months Ended March ,Markets ,